Medicine and Dentistry
Biliary Tract Cancer
100%
Overall Survival
90%
Neuroendocrine Tumor
69%
Diseases
51%
Cholangiocarcinoma
43%
Neoplasm
42%
Neuroendocrine Carcinoma
38%
Progression Free Survival
36%
Malignant Neoplasm
35%
Meta-Analysis
32%
Pancreas Cancer
31%
Gemcitabine
31%
Prognostic Factor
24%
Cisplatin
24%
Pancreas Adenocarcinoma
23%
Surgery
19%
Systemic Therapy
17%
Electrocorticography
15%
Lymphocyte
15%
Retrospective Study
14%
Neutrophil
14%
Bile Duct Cancer
13%
Pancreas Islet Cell Tumor
13%
Proportional Hazards Model
13%
Molecular Profiling
13%
Gallbladder Cancer
12%
Metastatic Carcinoma
12%
Hepatocellular Carcinoma
12%
Symptom
11%
Prevalence
10%
Primary Tumor
10%
Adjuvant Chemotherapy
9%
Hazard Ratio
9%
Docetaxel
9%
Phase II Trials
9%
Irinotecan
9%
Adenocarcinoma
9%
Everolimus
9%
Etoposide
9%
Biological Marker
9%
Radiation Therapy
8%
Glioblastoma
8%
Immunoreactive Insulin
8%
Bone Metastasis
8%
Supportive Care
8%
Folinic Acid
8%
Fluorouracil
8%
Survival Rate
8%
Exocrine Pancreatic Insufficiency
8%
Arm
8%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
52%
Biliary Tract Cancer
49%
Chemotherapy
45%
Neuroendocrine Tumor
33%
Neoplasm
29%
Neuroendocrine Carcinoma
28%
Disease
27%
Gemcitabine
27%
Cisplatin
26%
Progression Free Survival
24%
Malignant Neoplasm
21%
Pancreas Cancer
19%
Pancreas Adenocarcinoma
17%
Liver Cell Carcinoma
16%
Temozolomide
16%
Etoposide
13%
Bile Duct Carcinoma
13%
Biological Marker
13%
Glioblastoma
12%
Everolimus
10%
Exocrine Pancreatic Insufficiency
9%
Carboplatin
9%
Immunoreactive Insulin
8%
Docetaxel
8%
Placebo
8%
Sorafenib
7%
Phase II Trials
7%
Observational Study
7%
Carcinoid Syndrome
7%
Durvalumab
7%
Solid Malignant Neoplasm
6%
Pancreas Islet Cell Tumor
6%
Prevalence
6%
Irinotecan
6%
Systemic Treatment
6%
Capecitabine
6%
Gastroenteropancreatic Neuroendocrine Tumor
6%
Survival Rate
6%
Folinic Acid
6%
Axitinib
5%
Dexamethasone
5%
Fluorouracil
5%
Bile Duct Cancer
5%
Rivaroxaban
5%